<DOC>
	<DOCNO>NCT00221299</DOCNO>
	<brief_summary>The purpose study learn one year treatment parathyroid hormone ( PTH ) , either alone risedronate , increase thickness bone hip spine subject osteoporosis chronic low dose steroid use . During second year , study also look whether take risedronate preserve bone thickness create one year rhPTH 1-34 treatment .</brief_summary>
	<brief_title>Risedronate Parathyroid Hormone Reverse Osteoporosis Caused Chronic Steroid Use</brief_title>
	<detailed_description>Dr. Nancy Lane colleague University California , Davis University California , San Francisco conduct 2-year study human parathyroid hormone ( rhPTH 1-34 ) alone , rhPTH ( 1-34 ) risedronate compare risedronate alone men woman osteopenia chronic low dose glucocorticoid ( GC ) . This investigator-initiated study fund Aventis Pharmaceuticals . The study divide 2 phase . All study subject receive supplemental calcium citrate Vitamin D 2-year study . In year one subject randomly assign receive PTH ( subcutaneously daily ) placebo risedronate tablet placebo . In year two , PTH stop subject group 1 re-randomized receive risedronate tablet placebo . Subjects group 2 3 continue risedronate tablet . In year one study , subject randomly assign one follow treatment group . 1 . Group 1 : rhPTH ( 1-34 ) ( 20ug subcutaneously daily ) + riesdronate placebo tablets 2 . Group 2 : rhPTh ( 1-34 ) ( 20ug subcutaneously daily ) + risedronate tablet ( 35mg/wk ) 3 . Group 3 : rhPTh placebo ( subcutaneous injection normal saline ) + risedronate tablet ( 35mg/wk ) In year two study , begin 12 month timepoint 1 . Group 1 subject re-randomized either : Group 1a : risedronate ( 35mg/wk ) Group 1b : risedronate placebo 2 . Group 2 subject continue risedronate ( 35mg/wk ) 3 . Group 3 subject continue risedronate ( 35mg/wk ) Potential study subject dual x-ray absorptiometry measurement ( DEXA ) spine hip screen visit . Those study subject meet inclusion criterion invite back baseline visit . DEXA scan spine , hip , forearm do Baseline visit , 6-month , 12-month , 18-month , 24-month follow-up visit . DEXA scan spine , hip , forearm take approximately 20 minute complete . To assess incident vertebral non-vertebral fracture , lateral thoracic lumbar spine evaluation use Instant Vertebral Assessment [ IVA ] do Baseline , 12-month , 24-month follow-up visit . The specific aim study follow : 1 . To determine change bone mineral density spine hip cause 1 year treatment rhPTH ( 1-34 ) alone follow risedronate rhPTH ( 1-34 ) risedronate great PTH placebo risedronate patient GIO take calcium , MVIs chronic low dos glucocorticoid . 2 . To determine risedronate preserve high bone mass state create 1 year rhPTH ( 1-34 ) treatment . 3 . To determine association biochemical marker bone turnover rhPTH ( 1-34 ) risedronate treatment . 4 . To compare , possible , fracture incidence rhPTH ( 1-34 ) alone follow risedronate , rhPTH ( 1-34 ) risedronate compare risedronate + placebo group .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Men woman , great 18 year age history glucocorticoid therapy prednisone ≥ 7.5mg/d 6 month , currently prednisone ≥ 5mg /day . DXA lumbar spine ( L1L4 ) total hip femoral neck T score ≤ 1.5 without prevalent vertebral fracture . ( The T score number standard deviation population mean young , normal premenopausal female age 30 ) . Investigators satisfy physical condition would prevent patient receive propose treatment regimens . Patient ambulatory able return site investigation specify time study . The patient willing participate propose study evidence sign informed consent . Women childbearing age willing use 2 form contraception entire study period . Have least one analyzable BMD site : lumbar spine and/or proximal femur Generalized disease bone relate rheumatic disease glucocorticoidinduced osteoporosis include : hyperparathyroidism , hypoparathyroidism , Paget 's disease bone Diseases may affect bone metabolism include : alcoholism , hyperthyroidism , renal impairment ( creatinine &gt; 2.5mg/dl ) hepatic impairment ( SGOT level &gt; 2x upper limit normal Urinary excretion calcium &gt; 400mg/day History drug abuse Previous use alendronate within 6 month prior study Previous use risedronate , hormone replacement therapy calcitonin within 2 month prior study History unstable cardiovascular disease uncontrolled hypertension Severe scoliosis , great 2 lumbar fracture , spinal surgery precise bone mass measurement could affect History gastrointestinal intolerance bisphosphonates History cancer within 5 year study Patients glucocorticoid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Steroids</keyword>
	<keyword>Prednisone</keyword>
</DOC>